Trial
NCT03499041
A Study of LY3314814 in Participants With Liver Impairment
Phase IWITHDRAWNEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
AstraZeneca
Condition
Hepatic Impairment
Intervention
LY3314814
Why stopped
Stopped for futility. Phase 3 studies not likely to meet primary endpoints.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-06-28